Clostridium difficile infection and treatment in the pediatric inflammatory bowel disease population

Journal of Pediatric Gastroenterology and Nutrition

Volumn 52, Issue 4, 2011, Pages 437-441

  Mezoff, Ethan ^a   Mann, Elizabeth A ^a   Hart, Kim Ward ^a   Lindsell, Christopher J ^a,b   Cohen, Mitchell B ^a,b  

^a CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

^b UNIVERSITY OF CINCINNATI COLLEGE OF MEDICINE   (United States)

Author keywords

Clostridium difficile; inflammatory bowel disease; metronidazole; vancomycin

Indexed keywords

ADALIMUMAB; AMINOSALICYLIC ACID; CLOSTRIDIUM DIFFICILE TOXIN A; CLOSTRIDIUM DIFFICILE TOXIN B; IMMUNOGLOBULIN G; IMMUNOMODULATING AGENT; INFLIXIMAB; MERCAPTOPURINE; METHOTREXATE; METRONIDAZOLE; NITAZOXANIDE; PROBIOTIC AGENT; PROTON PUMP INHIBITOR; RIFAXIMIN; STEROID; VANCOMYCIN; ZIDOVUDINE;

ARTICLE; CHI SQUARE DISTRIBUTION; CHILD; CLINICAL ARTICLE; CLOSTRIDIUM DIFFICILE; CLOSTRIDIUM DIFFICILE INFECTION; ENTERITIS; FEMALE; FISHER EXACT TEST; HUMAN; INCIDENCE; MALE; PRIORITY JOURNAL; STUDENT T TEST; TREATMENT FAILURE; TREATMENT OUTCOME;

ADOLESCENT; ANTI-BACTERIAL AGENTS; BACTERIAL PROTEINS; BACTERIAL TOXINS; CHILD; CLOSTRIDIUM DIFFICILE; DRUG THERAPY, COMBINATION; ENTEROCOLITIS, PSEUDOMEMBRANOUS; ENTEROTOXINS; FECES; FEMALE; HOSPITALS, PEDIATRIC; HUMANS; INCIDENCE; INFLAMMATORY BOWEL DISEASES; MALE; METRONIDAZOLE; OHIO; RECURRENCE; RETROSPECTIVE STUDIES; VANCOMYCIN;

CLOSTRIDIUM DIFFICILE;

EID: 79953809460     PISSN: 02772116     EISSN: None     Source Type: Journal    
DOI: 10.1097/MPG.0b013e3181f97209     Document Type: Article

References (14)

1. Kelly CP, LaMont JT. Clostridium difficile - more difficult than ever. N Engl J Med 2008;359:1932-40.
2. McFarland LV. Update on the changing epidemiology of Clostridium difficile-associated disease. Nat Clin Pract 2008;5:40-8.
3. Lowy I, Molrine DC, Leav BA, et al. Treatment with monoclonal antibodies against Clostridium difficile toxins. N Engl J Med 2010;362:197-205.
4. Issa M, Vijayapal A, Graham MB, et al. Impact of Clostridium difficile on inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:345-51. (Pubitemid 46401531)
5. Rodemann JF, Dubberke ER, Reske KA, et al. Incidence of Clostridium difficile infection in inflammatory bowel disease. Clin Gastroenterol Hepatol 2007;5:339-44. (Pubitemid 46401530)
6. Nguyen GC, Kaplan GG, Harris ML, et al. A national survey of the prevalence and impact of Clostridium difficile infection among hospitalized inflammatory bowel disease patients. Am J Gastroenterol 2008;103:1443-50. (Pubitemid 351813903)
7. Clayton EM, Rea MC, Shananhan F, et al. The vexed relationship between Clostridium difficile and inflammatory bowel disease: an assessment of carriage in an outpatient setting among patients in remission. Am J Gastroenterol 2009;104:1162-9.
8. Pascarella F, Martinelli M, Miele E, et al. Impact of Clostridium difficile infection on pediatric inflammatory bowel disease. J Pediatr 2009;154:854-8.
9. Kim J, Smathers SA, Prasad P, et al. Epidemiological features of Clostridium difficile-associated disease among inpatients at children's hospitals in the United States, 2001-2006. Pediatrics 2008;122:1266-70.
10. Benson L, Song X, Campos J, et al. Changing epidemiology of Clostridium difficile-associated disease in children. Infect Control Hosp Epidemiol 2007;28:1233-5. (Pubitemid 47596560)
11. Mylonaki M, Langmead L, Pantes A, et al. Enteric infection in relapse of inflammatory bowel disease: importance of microbiological examination of stool. Eur J Gastroenterol Hepatol 2004;16:775-8. (Pubitemid 39062569)
12. Meyer AM, Ramzan NN, Loftus EV, et al. The diagnostic yield of stool pathogen studies during relapses of inflammatory bowel disease. J Clin Gastroenterol 2004;38:772-5. (Pubitemid 39274178)
13. Ben-Horin S, Margalit M, Bossuyt P, et al. Combination immunomodulator and antibiotic treatment in patients with inflammatory bowel disease and Clostridium difficile infection. Clin Gastroenterol Hepatol 2009;7:981-7.
14. Bantel H, Berg C, Vieth M, et al. Mesalazine inhibits activation of transcription factor NF-kappaB in inflamed mucosa of patients with ulcerative colitis. Am J Gastroenterol 2000;95:3452-7.